Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP1302 for Graves' Disease Relapse Prevention
NCT06240455Phase 2Suspended
- Sponsor
- Worg Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of WP1302 in Graves' disease (4 arms), sponsored by Worg Pharmaceuticals. Primary endpoint: Relapse rate at 42 weeks. Started Mar 2026; status: suspended.
02
Drugs
WP1302
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT06240455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06240455.